Top

Intensive Care Medicine

Published in:

01-12-2004 | Review

Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness

Authors: Rina Mehrotra, Raffaele De Gaudio, Mark Palazzo

Published in: Intensive Care Medicine | Issue 12/2004

Abstract

Background

Many factors over which there may be little control may influence the response of a patient to therapy. However, therapy with antibiotics can be readily optimised.

Discussion

Concentration-dependent agents such as aminoglycosides appear effective and to entail fewer side effects when given in large, infrequent doses. There is also evidence that time-dependent antibiotics often fail to reach adequate concentrations throughout the treatment period. To date no randomised controlled prospective trial has demonstrated improvement in clinical outcome following infusion rather than intermittent boluses of time-dependent antibiotics. Critical illness alters antibiotic pharmacokinetics principally through increases in volume of distribution. Other than glycopeptides and aminoglycosides, antibiotic blood concentrations are rarely monitored and therefore adequate concentrations can only be inferred from clinical response.

Conclusions

Failure to respond within the first few days of empirical treatment may be due to antibiotic resistance or inadequate doses. Therefore the same rigor should be applied to achieving adequate antibiotic concentrations as is applied to inotropes, which are titrated to achieve predetermined physiological targets

McCabe WR, Jackson GG (1962) Gram negative bacteremia, 11. Clinical, laboratory, and therapeutic observations. Arch Intern Med 110:92–100

Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355CrossRefPubMed

Rello J, Gallego M, Mariscal D, Sonora R, Valles J (1997) The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156:196–200PubMed

Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474CrossRefPubMed

Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36:1418–1423CrossRefPubMed

MacGowan AP, Wise R (2001) Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48 [Suppl 1]:17–28

Bryan CS, Reynolds KL, Brenner ER (1983) Analysis of 1:186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 5:629–638PubMed

Lorian V, Burns L (1990) Predictive value of susceptibility tests for the outcome of antibacterial therapy. J Antimicrob Chemother 25:175–181PubMed

Eagle H, Fleischman R, Musselman A (1950) Effect of schedule of adminstration on the therapeutic efficacy of penicillin. Am J Med 9:280–299CrossRefPubMed

10.

Vogelman B, Craig WA (1986) Kinetics of antimicrobial activity. J Pediatr 108:835–840PubMed

11.

Gerber AU, Feller Segessenmann C (1985) In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 15 Suppl A:201–206

12.

Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL (1988) An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 44:232–238PubMed

13.

Benko AS, Cappelletty DM, Kruse JA, Rybak MJ (1996) Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 40:691–695PubMed

14.

Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931–936PubMed

15.

Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA (1997) In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 41:2053–2056PubMed

16.

Eagle H, Musselman A (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88:99–131CrossRef

17.

Craig WA, Ebert SC (1990) Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 74:63–70PubMed

18.

Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521–527PubMed

19.

Eagle H, Fleischman R, Musselman AD (1950) The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. Ann Intern Med 33:544–571PubMed

20.

Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA (1988) In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157:287–298PubMed

21.

Gudmundsson S, Vogelman B, Craig WA (1986) The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 18 Suppl E:67–73

22.

Hostacka A, Karelova E (1997) Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem. Microbios 90:45–50PubMed

23.

Fuentes F, Martin MM, Izquierdo J, Gomez Lus ML, Prieto J (1995) In vivo and in vitro study of several pharmacodynamic effects of meropenem. Scand J Infect Dis 27:469–474

24.

Hanberger H, Svensson E, Nilsson LE, Nilsson M (1995) Pharmacodynamic effects of meropenem on gram-negative bacteria. Eur J Clin Microbiol Infect Dis 14:383–390

25.

Turnidge JD, Gudmundsson S, Vogelman B, Craig WA (1994) The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 34:83–92PubMed

26.

Andes D, van Ogtrop M (1999) Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43:2116–2120PubMed

27.

Barza M (1994) Challenges to antibiotic activity in tissue. Clin Infect Dis 19:910–915PubMed

28.

Gerding DN, Van Etta LL, Peterson LR (1982) Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime. Antimicrob Agents Chemother 22:844–847PubMed

29.

Wise R, Gillett AP, Cadge B, Durham SR, Baker S (1980) The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis 142:77–82PubMed

30.

Merrikin DJ, Briant J, Rolinson GN (1983) Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 11:233–238

31.

Chambers HF, Mills J, Drake TA, Sande MA (1984) Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis 6 Suppl 4:S870–874

32.

Van Etta LL, Peterson LR, Fasching CE, Gerding DN (1982) Effect of the ratio of surface area to volume on the penetration of antibiotics in to extravascular spaces in an in vitro model. J Infect Dis 146:423–428PubMed

33.

Lambert HP (1978) Clinical significance of tissue penetration of antibiotics in the respiratory tract. Scand J Infect Dis Suppl 14:262–266PubMed

34.

Pennington JE (1981) Penetration of antibiotics into respiratory secretions. Rev Infect Dis 3:67–73PubMed

35.

Echols RM (1993) The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother 31:783–787PubMed

36.

Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073–1081PubMed

37.

Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S (1998) Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 42:2235–2239PubMed

38.

Highet VS, Forrest A, Ballow CH, Schentag JJ (1999) Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 43 [Suppl A]:55–63

39.

Rotschafer JC, Zabinski RA, Walker KJ (1992) Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 12:64s–70 sPubMed

40.

Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE (1997) Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 40:269–273CrossRefPubMed

41.

Ronchera Oms CL, Gregorio S, Sanllehi N (1997) Should continuous infusion of beta-lactam antibiotics be the first-line approach? J Clin Pharm Ther 22:159–161CrossRefPubMed

42.

Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523–527CrossRefPubMed

43.

Lipman J, Gomersall C, Gin T, Joynt GM, Young R J (1999) Continuous infusion ceftazidime in intensive care: a randomised controlled trial. J Antimicrob Chemother 43:309–311CrossRefPubMed

44.

MacGowan AP, Bowker KE (1998) Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 35:391–402PubMed

45.

Peterson LR, Gerding DN, Fasching CE (1981) Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion. J Antimicrob Chemother 7:71–79PubMed

46.

Roosendaal R, Bakker Woudenberg IA (1990) Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand J Infect Dis Suppl 74:155–162PubMed

47.

Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF (1990) Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 34:2307–2311PubMed

48.

Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160PubMed

49.

Jawetz E (1946) Dynamics of the action of penicillin in experimental animals. Arch Intern Med 77:1–16

50.

Ljungberg B, Nilsson Ehle I (1989) Advancing age and acute infection influence the kinetics of ceftazidime. Scand J Infect Dis 21:327–332PubMed

51.

Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE (1990) Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 18:37–41PubMed

52.

Gomez CM, Cordingly JJ, Palazzo MG (1999) Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 43:1798–1802PubMed

53.

Lipman J, Wallis SC, Rickard C (1999) Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43:2559–2561PubMed

54.

Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough DD (1991) Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 35:57–61PubMed

55.

Boucher BA, Kuhl DA, Hickerson WL (1992) Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 14:458–463

56.

Bourget P, Lesne Hulin A, Le Reveille R, Le Bever H, Carsin H (1996) Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40:139–145PubMed

57.

Fantin B, Farinotti R, Thabaut A, Carbon C (1994) Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 33:563–569PubMed

58.

Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R (1996) Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 40:61–64PubMed

59.

Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, Le Conte P, Baron D, Potel G (2001) In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother 47:617–622CrossRefPubMed

60.

Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH (2001) Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 17:497–504CrossRefPubMed

61.

Bodey GP, Ketchel SJ, Rodriguez V (1979) A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67:608–616CrossRefPubMed

62.

Harding I, MacGowan AP, White LO, Darley ES, Reed V (2000) Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 45:835–841CrossRefPubMed

63.

Brinquin L, Rousseau JM, Boulesteix G, Diraison Y, Bonsignour JP (1993) Continuous infusion of vancomycin in post-neurosurgical staphylococcal meningitis in adults. Presse Med 22:1815–1817PubMed

64.

Conil JM, Favarel H, Laguerre J, Brouchet A, Chabanon G, Cazal L, Bodnar M, Rouge D, Virenque C, Costagliola M (1994) Continuous administration of vancomycin in patients with severe burns. Presse Med 23:1554–1558PubMed

65.

Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E (1996) Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38:865–869PubMed

66.

Di Filippo A, De Gaudio AR, Novelli A, Paternostro E, Pelagatti C, Livi P, Novelli GP (1998) Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy 44:63–68CrossRefPubMed

67.

Albanese J, Leone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C (2000) Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 44:1356–1358CrossRefPubMed

68.

Gauzit R (2002) [The use of glycopeptides in intensive care and anaesthesia]. Ann Fr Anesth Reanim 21:414–417CrossRefPubMed

69.

Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D (2001) Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45:2460–2467CrossRefPubMed

70.

Byl B, Jacobs F, Wallemacq P, Rossi C, de Francquen P, Cappello M, Leal T, Thys JP (2003) Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 47:2015–2017CrossRefPubMed

71.

Jacqueline C, Batard E, Perez L, Boutoille D, Hamel A, Caillon J, Kergueris MF, Potel G, Bugnon D (2002) In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 46:3706–3711CrossRefPubMed

72.

Pennington JE, Dale DC, Reynolds HY, MacLowry JD (1975) Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis 132:270–275PubMed

73.

Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A (1990) Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 16:303–306PubMed

74.

Triginer C, Izquierdo I, Fernandez R, Torrent J, Benito S, Net A, Jane F (1991) Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol 40:297–302PubMed

75.

Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93–99PubMed

76.

Deziel Evans LM, Murphy JE, Job ML (1986) Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 5:319–324PubMed

77.

Jackson GG, Lolans VT, Daikos GL (1990) The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 162:408–413PubMed

78.

Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ (1994) Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 33:937–947PubMed

79.

Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. (ÎÎ1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43:623–629

80.

Ali MZ, Goetz MB (1997) A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:796–809PubMed

81.

Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC (1997) A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:786–795PubMed

82.

Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312:338–345PubMed

83.

Munckhof WJ, Grayson ML, Turnidge JD (1996) A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37:645–663PubMed

84.

Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549–1555PubMed

85.

Moore RD, Smith CR, Lietman PS (1984) Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149:23–30PubMed

86.

Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS (1984) Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100:352–357PubMed

87.

Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R (1995) Experience with a once-daily aminoglycoside program administered to 2:184 adult patients. Antimicrob Agents Chemother 39:650–655PubMed

88.

Bauernfeind A (1993) Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 31:789–798PubMed

89.

Neu HC, Kumada T, Chin NX, Mandell W (1987) The post-antimicrobial suppressive effect of quinolone agents. Drugs Exp Clin Res 13:63–67PubMed

90.

Alados JC, Gutierrez J, Garcia F, Liebana J, Piedrola G (1990) Post-antibiotic effect of three quinolones against gram negative isolates from urine. Med Lab Sci 47:272–277PubMed

91.

Fuentes F, Martin MM, Izquierdo J, Gomez Lus ML, Prieto J (1996) Pharmacodynamic effects of ciprofloxacin, fleroxacin and lomefloxacin in vivo and in vitro. Chemotherapy 42:354–362PubMed

92.

Fung Tomc J, Kolek B, Bonner DP (1993) Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 37:1289–1296PubMed

93.

Van der Auwera P, Matsumoto T, Husson M (1988) Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 22:185–192PubMed

94.

Gerding DN, Hall WH, Schierl EA (1977) Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis. Ann Intern Med 86:708–713PubMed

95.

Thys JP, Vanderhoeft P, Herchuelz A, Bergmann P, Yourassowsky E (1988) Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest 93:530–532PubMed

96.

Vacek V, Hejzlar M, Skalova M (1969) Penetration of antibiotics into the cerebro-spinal fluid in inflammatory conditions. 3. Gentamicin. Int Z Klin Pharmakol Ther Toxikol 2:277–279PubMed

97.

Grange JD, Gouyette A, Gutmann L, Amiot X, Kitzis MD, Islam S, Acar JF, Jaillon P (1989) Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patients. J Antimicrob Chemother 23:605–611PubMed

98.

Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D (1994) Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 49:1134–1138PubMed

99.

Jacobs RF, Thompson JW, Kiel DP, Johnson D (1986) Cellular uptake and cell-associated activity of third generation cephalosporins. Pediatr Res 20:909–912PubMed

100.

Kummel A, Schlosser V, Petersen E, Daschner FD (1985) Pharmacokinetics of imipenem-cilastatin in serum and tissue. Eur J Clin Microbiol Infect Dis 4:609–610

101.

Rolando N, Wade JJ, Philpott Howard JN, Casewell MW, Williams R (1994) The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. J Antimicrob Chemother 33:163–167PubMed

102.

Muller Serieys C, Bergogne Berezin E, Rowan C, Dombret MC (1987) Imipenem penetration into bronchial secretions. J Antimicrob Chemother 20:618–619PubMed

103.

Mayer M, Tophof C, Opferkuch W (1988) Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. Infection 16:225–228PubMed

104.

Hand WL, King Thompson NL (1989) The entry of antibiotics into human monocytes. J Antimicrob Chemother 23:681–689PubMed

105.

Runyon BA, Akriviadis EA, Sattler FR, Cohen J (1991) Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci 36:1782–1786PubMed

106.

Soussy CJ, Deforges LP, Le Van Thoi J, Feghali W, Daval JR (1980) Cefotaxime concentration in the bile and wall of the gallbladder. J Antimicrob Chemother 6:A125–A130

107.

Lode H, Kemmerich B, Gruhlke G, Dzwillo G, Koeppe P, Wagner I (1980) Cefotaxime in bronchopulmonary infections-a clinical and pharmacological study. J Antimicrob Chemother 6:A193–A198

108.

Belohradsky BH, Bruch K, Geiss D, Kafetzis D, Marget W, Peters G (1980) Intravenous cefotaxime in children with bacterial meningitis. Lancet I:61–63CrossRef

109.

Lechi A, Arosio E, Xerri L, Mengoli C, Montesi G, Ghidini O (1982) The kinetics of cefuroxime in ascitic and pleural fluid. Int J Clin Pharmacol Ther 20:493–496

110.

Swedish Study Group (1982) Cefuroxime versus ampicillin and chloramphenicol for the treatment of bacterial meningitis. Report from a Swedish study group. Lancet I:295–299

111.

Koga H (1987) High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother 31:1904–1908PubMed

112.

Adam D, Reichart B, Williams KJ (1983) Penetration of ceftazidime into human tissue in patients undergoing cardiac surgery. J Antimicrob Chemother 12:A269–A273

113.

Benoni G, Arosio E, Raimondi MG, Pancera P, Lechi A, Velo GP (1985) Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid. J Antimicrob Chemother 16:267–273PubMed

114.

Maderazo EG, Breaux SP, Woronick CL, Quintiliani R, Nightingale CH (1988) High teicoplanin uptake by human neutrophils. Chemotherapy 34:248–255PubMed

115.

Lanao JM, Dominguez Gil A, Macias JG, Diez JL, Nieto MJ (1980) The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol 18:57–61

116.

Dull WL, Alexander MR, Kasik JE (1979) Bronchial secretion levels of amikacin. Antimicrob Agents Chemother 16:767–771PubMed

117.

Bermudez RH, Lugo A, Ramirez Ronda CH, Amadeo JA, Morales J (1981) Amikacin sulfate levels in human serum and bile. Antimicrob Agents Chemother 19:352–354PubMed

118.

Yogev R, Kolling WM (1981) Intraventricular levels of amikacin after intravenous administration. Antimicrob Agents Chemother 20:583–586PubMed

119.

Hary L, Smail A, Ducroix JP, Baillet J, Andrejak M (1991) Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin Pharmacol 5:789–795PubMed

120.

Mouton Y, Caillaux M, Deboscker Y, Beuscart C, Beaucaire G, Fourrier A (1985) Etude de la diffusion bronchique de la piperacilline chez dix-huit patients de reanimation. Pathol Biol (Paris) 33:359–362

121.

Brogard JM, Jehl F, Blickle JF, Dorner M, Arnaud JP, Monteil H (1990) Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. Int J Clin Pharmacol 28:462–470

122.

Gerding DN, Hitt JA (1989) Tissue penetration of the new quinolones in humans. Rev Infect Dis 11:5s1046–1057

123.

Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V (1986) Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 29:405–408PubMed

124.

Reid TM, Gould IM, Golder D, Legge JS, Douglas JG, Friend JA, Watt SJ (1989) Respiratory tract penetration of ciprofloxacin. Am J Med 87:60s-61 sCrossRefPubMed

125.

Joseph J, Vaughan LM, Basran GS (1994) Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother 28:313–315PubMed

Title: Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness
Authors: Rina Mehrotra
Raffaele De Gaudio
Mark Palazzo
Publication date: 01-12-2004
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 12/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-004-2428-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness

Abstract

Background

Discussion

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Discussion

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2004

Reasons for the higher incidence of unplanned extubation in medical ICUs than in surgical ICUs: reply to the letter by F. Kapadia

Superior vena cava collapsibility as a gauge of volume status in ventilated septic patients

Septic diaphragmatic dysfunction is prevented by Mn(III)porphyrin therapy and inducible nitric oxide synthase inhibition

The neuroendocrine stress response and severity of acute respiratory syncytial virus bronchiolitis in infancy

Sustained moderate reductions in arterial CO2 after brain trauma Time-course of cerebral blood flow velocity and intracranial pressure

Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects